Date:3/23/2011

g, global aesthetic treatments.  The company pioneered the development of multi-source radiofrequency technology, branded 3DEEP© RF, which is used in micro-ablative fractional and non-ablative aesthetic treatments. 3DEEP RF enables safe and effective results with minimal recovery time.  In August 2009, the EndyMed PRO multi-application platform was the world's first multi-source non-ablative radiofrequency device to be FDA cleared for the treatment of mild to moderate facial wrinkles.  In February 2011, the EndyMed PRO Fractional Skin Resurfacing Applicator, which enables simultaneous epidermal fractional ablation and deep dermal volumetric heating, became the world's first multi-source, fractionally ablative radiofrequency device to be FDA cleared for skin resurfacing.

EndyMed's management, clinical, marketing and R&D teams have extensive experience in the medical aesthetic market.  With proprietary 3DEEP radiofrequency technology and proprietary products like EndyMed PRO, the company is committed to changing the way aesthetic professionals perform fractional skin resurfacing, treat wrinkles, and provide skin tightening and body contouring solutions. EndyMed markets and supports its products in an ever increasing number of countries globally. Contact:  

Ann Berzak(m) +972 54 300 3269(e)  annb@endymed.comwww.endymed.comDistributor in USA:Eclipse Aesthetics, LLC.(t) 972 380 2911www.eclipseaesthetics.com©2011 EndyMed Medical, Ltd. All rights reserved. EndyMed Medical™, EndyMed PRO™ 3DEEP® and 3DEEP Fractional Skin Resurfacing™ are trademarks or registered trademarks of EndyMed Medical, Ltd.

'/>"/>

SOURCE EndyMed Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Alzheimers Drug Discovery Foundation Supports ADispell Technology with a Grant to Advance Novel Drug Candidates for Alzheimers Disease
2. Novel Gene Therapy Agent NLX-P101 Effective in Treating Parkinsons Disease in Phase 2 Trial
3. Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
4. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
5. S*BIOs Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models
6. Reportlinker Adds Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin
7. Boston Scientific Acquires Two Novel Technologies to Treat Peripheral Chronic Total Occlusions
8. ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination
9. Tolerx Presents Preclinical Data on Novel Cancer Immunotherapeutic, TRX518, a First-in-Class Anti-GITR Antibody
10. Endo Pharmaceuticals and Orion Corporation Begin Novel R&D Collaboration
11. Novel Night Time Healing is Key to Shoulder Pain Relief From ROTATORELIEVER